Holly Heaslet Soutter, Ph.D.

Holly Soutter is director of the lead discovery and profiling group within the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. Her research unit supports projects across multiple therapeutic areas to identify, validate, and mechanistically characterize potential small and large molecule therapeutics. Her team has expertise in multiple areas including automation, compound management, assay development, high-throughput screening, biophysical interaction analysis (small and large molecules), mass spectrometry, enzymology, and many others.

Soutter brings 20 years of experience in drug discovery and development to CDoT. She is co-inventor of multiple clinical candidates, and has co-authored more than 20 scientific publications. Before coming to the Broad in 2020, she led the biochemistry and biophysics group at Silicon Therapeutics, an immuno-oncology focused drug discovery company. She has extensive expertise in DNA-encoded library technologies, having worked at X-Chem for 6 years prior to joining Silicon.

She is an associate member of the Dana-Farber/Harvard Cancer Center (DF/HCC) Breast Cancer and Developmental Therapeutics programs. She received her B.A. in chemistry from Hunter College, and her M.A. and Ph.D. in chemistry from Clark University.

Contact Holly Soutter via email at hsoutter@broadinstitute.org.